Breast Cancer Drug Wins Approval Despite Rejection by Agency Advisors

Breast Cancer Drug Wins Accelerated Approval Four Months After FDA Advisers Voted Six to Three Against It

FDA granted camizestrant accelerated approval for ESR1-mutated breast cancer months after its advisory committee voted against the application.

AstraZeneca’s breast cancer pill gets approval from the FDA

AstraZeneca Plc’s breast cancer pill was approved by the U.S.

Breast Cancer Drug Wins Approval Despite Rejection by Agency Advisors

(MedPage Today) -- The FDA on Friday granted accelerated approval to camizestrant (Etcamah) for treating hormone receptor-positive/HER2-negative breast cancer at the first sign of ESR1 resistance mutations during first-line treatment. Camizestrant...

FDA approves AstraZeneca breast cancer drug

Today's biotech news covers Roivant drug delivers mid-stage results, Moonwalk raises funds to develop longer-lasting obesity drugs, etc.

FDA Approves Camizestrant for ESR-1 Mutated Breast Cancer

This is the first approval based on a resistance mutation detected before standard imaging The U.S. Food & Drug Administration (FDA) granted accelerated approval to Etcamah (camizestrant), in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for adults with hormone receptor (HR)-positive/HER2-negative, locally advanced or metastatic breast cancer with an estrogen receptor-1 (ESR1) mutation […]